Vaxcell-Bio Therapeutics Logo

Vaxcell-Bio Therapeutics

Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.

323990 | KO

Overview

Corporate Details

ISIN(s):
KR7323990002
LEI:
Country:
South Korea
Address:
전라남도 화순군 화순읍 산단길 12-55, 화순군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of anti-cancer immunotherapies. The company's core R&D is centered on its proprietary Natural Killer (NK) cell and Chimeric Antigen Receptor (CAR) technology platforms, developing advanced CAR-T and CAR-NK cell therapies. Its pipeline targets a range of malignancies, including liver cancer, pancreatic cancer, small cell lung cancer, and other solid tumors. A notable product, Vaxleukin-15, is an approved immunotherapy adjunct for canine lymphoma. The company actively secures intellectual property for its novel methods of manufacturing high-purity immune cells, positioning itself as a key developer in patient-specific cancer treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항 (박스루킨-15주 (Vaxleukin-15 inj) 품목허가 변경신청 승인)
Korean 11.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-28 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.9 KB
2025-06-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 126.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 17.0 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 17.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 19.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 19.1 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 20.2 KB
2025-04-08 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 20.2 KB
2025-04-02 00:00
Regulatory News Service
유형자산취득결정(자율공시)
Korean 8.1 KB
2025-03-28 00:00
M&A Activity
[기재정정]합병등종료보고서(합병)
Korean 32.6 KB

Automate Your Workflow. Get a real-time feed of all Vaxcell-Bio Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vaxcell-Bio Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vaxcell-Bio Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden
ERMA
Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.